GlaxoSmithKline said its Chinese unit would pay a fine of about £300m after it was found guilty of bribing non-government personnel in the country following a long-running and high-profile investigation.
GSK said in a statement on Friday that it would pay the equivalent of Rmb 3bn (£297m) to the Chinese government - a hefty penalty in the country - after a court ruled that GSK China Investment Co. Ltd (GSKCI) had "offered money or property to non-government personnel in order to obtain improper commercial gains".
From its statement:
您已閱讀31%（536字），剩餘69%（1179字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。